We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Particle Characterization System Critical to Development of Brain Tumor Illumination

By HospiMedica International staff writers
Posted on 05 Feb 2010
A particle characterization system is proving to be a creative research tool for advanced healthcare applications such as gene therapy and selective-target carrier molecules. More...


The University of Washington (Seattle, WA, USA) researchers reported that accurate zeta potential and particle size measurements were critical to their successful development of fluorescent, tumor-targeting iron oxide nanoparticles. Able to safely cross the blood-brain barrier and selectively illuminate brain cancer cells during a magnetic resonance imaging (MRI) scan, the innovative molecules resulting from this research should make brain cancer imaging much safer.

"Safe molecular penetration of the blood-brain barrier depends on a particle's size, fat content, and electric charge. It wasn't until we obtained the Zetasizer Nano in 2006 that we were able to efficiently measure, monitor, and optimize these properties and develop nanoparticles that deliver the desired half-life in blood but remain stable long enough to support imaging,” explained Prof. Miqin Zhang, from the University of Washington's department of materials science and engineering. The Zetasizer Nano system was developed by Malvern Instruments (Malvern, UK).

The blood-brain barrier protects the brain from infection. Current imaging techniques require the injection of both dyes and a drug to forcefully open the barrier. Prof. Zhang and her team have formulated particles approximately 33 nm in diameter. Three times smaller in wet conditions than anything previously formulated in the lab, these particles can naturally penetrate the blood-brain barrier without exposing the patient to the risk of infection, and represent a highly significant advance in brain cancer imaging.

The Nanoparticle Lab within the University of Washington's department of materials science and engineering focuses its research on cancer diagnosis and treatment through imaging enhancement and targeted and controlled therapeutic payload delivery. This is accomplished by use of nanoconjugates or multifunctional nanovectors. A nanoconjugate is a chemically modified nanoparticle serving as a "vehicle” that carries biomolecules to target cells. The term "nanovector” here refers to a nanosized entity that plays a functional role in the perspective of therapeutics.

Malvern Instruments provides a range of complementary materials characterization tools that deliver interrelated measurements reflecting the complexities of particulates and disperse systems, nanomaterials and macromolecules. Analytic instruments from Malvern are used in the characterization of a wide variety of materials, from industrial bulk powders to nanomaterials and delicate macromolecules. A wide range of innovative technologies is combined with intelligent, user-friendly software. These systems provide industrially relevant data enabling the customers to make the connection between micro (such as particle size) and macro (bulk) material properties (rheology) and chemical composition (chemical imaging).

Particle size, particle shape, zeta potential, molecular weight, chemical composition and rheologic properties measurements are combined by advanced chromatography systems (GPC/SEC), extending Malvern's technologies for protein molecular weight, size, and aggregation measurements, and synthetic polymer molecular weight and distribution.

Related Links:

University of Washington
Malvern Instruments



Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: 123RF

AI Platform Screens for Amyloid Cardiomyopathy Using ECG Images

Amyloid cardiomyopathy is a heart disease caused by deposits of misfolded proteins in the cardiac muscle. It is often missed until patients develop serious complications such as heart failure.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.